Provided by Tiger Trade Technology Pte. Ltd.

Allarity Therapeutics Inc

1.05
+0.08498.80%
Post-market: 1.080.0345+3.29%17:10 EDT
Volume:119.11K
Turnover:123.52K
Market Cap:16.61M
PE:-1.33
High:1.08
Open:0.9894
Low:0.9678
Close:0.9651
52wk High:1.84
52wk Low:0.7687
Shares:15.82M
Float Shares:15.79M
Volume Ratio:0.82
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7895
EPS(LYR):-0.7811
ROE:-157.09%
ROA:-25.31%
PB:4.70
PE(LYR):-1.34

Loading ...

Allarity updates on recent advances in Drug Response Predictor technology

TIPRANKS
·
Yesterday

Allarity Therapeutics Says Newly Awarded Patents Bolster Exclusivity Strategy for Stenoparib-DRP Test

Reuters
·
Yesterday

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development

THOMSON REUTERS
·
Yesterday

Allarity Therapeutics Expands In-House Lab to Add Proteomics, Cell Line Research

Reuters
·
Sep 28

Allarity Therapeutics Wins Japan Patent for Stenoparib DRP Companion Diagnostic

Reuters
·
Sep 16

Allarity Therapeutics - Japan Patent Office Grants Patent for Stenoparib Drp Companion Diagnostic

THOMSON REUTERS
·
Sep 15

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

GlobeNewswire
·
Sep 15

Allarity Therapeutics - Proposed IPO Base Offering Size $100 Mln, or $115 Mln with Full Over-Allotment

THOMSON REUTERS
·
Sep 11

Allarity Therapeutics - Allarity Acquisition Corp. Files Registration Statement for Proposed IPO

THOMSON REUTERS
·
Sep 11

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

THOMSON REUTERS
·
Sep 11

Allarity Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 15

Allarity Therapeutics Q2 Loss Narrows as Expenses Fall

Reuters
·
Aug 14

Allarity Therapeutics Q2 Net Loss Per Share $0.21

THOMSON REUTERS
·
Aug 14

Allarity Therapeutics Q2 Operating Expenses USD 2.671 Million

THOMSON REUTERS
·
Aug 14

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

GlobeNewswire
·
Aug 14

Allarity Therapeutics Inc Expected to Post a Loss of 25 Cents a Share - Earnings Preview

Reuters
·
Aug 13

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

GlobeNewswire
·
Jul 07

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib Drp® Companion Diagnostic

Reuters
·
Jul 06

Allarity Therapeutics - Has Patent Protection for Stenoparib Drp in Europe and Australia into 2039

THOMSON REUTERS
·
Jun 30

Allarity Therapeutics - Granted Patent Term Extends into April 2042

THOMSON REUTERS
·
Jun 30